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Abstract
Despite intensive studies, the clinical opportunities for patients with fibrosing liver diseases have
not improved. This will be changed by increasing knowledge of new pathogenetic mechanisms,
which complement the "canonical principle" of fibrogenesis. The latter is based on the activation of
hepatic stellate cells and their transdifferentiation to myofibroblasts induced by hepatocellular
injury and consecutive inflammatory mediators such as TGF-β. Stellate cells express a broad
spectrum of matrix components. New mechanisms indicate that the heterogeneous pool of (myo-
)fibroblasts can be supplemented by epithelial-mesenchymal transition (EMT) from cholangiocytes
and potentially also from hepatocytes to fibroblasts, by influx of bone marrow-derived fibrocytes
in the damaged liver tissue and by differentiation of a subgroup of monocytes to fibroblasts after
homing in the damaged tissue. These processes are regulated by the cytokines TGF-β and BMP-7,
chemokines, colony-stimulating factors, metalloproteinases and numerous trapping proteins. They
offer innovative diagnostic and therapeutic options. As an example, modulation of TGF-β/BMP-7
ratio changes the rate of EMT, and so the simultaneous determination of these parameters and of
connective tissue growth factor (CTGF) in serum might provide information on fibrogenic activity.
The extension of pathogenetic concepts of fibrosis will provide new therapeutic possibilities of
interference with the fibrogenic mechanism in liver and other organs.
Introduction
Experimental and clinical studies of the past twenty years
or so provide a detailed knowledge of structure and com-
position of extracellular matrix (ECM) in normal and
fibrotic liver tissue [1,2], of the cellular origin of the vari-
ous matrix components [3], of the cytokine- and growth
factor-regulated stimulation of ECM synthesis (fibrogene-
sis) and regulation of matrix degradation (fibrolysis) [4-
6], of several genetic conditions predisposing for fibro-
genesis [7,8], and of multiple, experimentally successful
therapeutic approaches [9]. However, up to now the clin-
ical benefit derived from basic research in the context of
translational medicine is scarce with regard to an effective,
harmless and site-directed antifibrotic therapy and
approved non-invasive diagnostic measures of the activity
of fibrogenesis ("grading") and/or of the extent of the
fibrotic organ transition ("staging") using serum parame-
ters [10]. The failure of clinical success boosts current
research on fibrosis and fibrogenesis not only of the liver,
but also of the lung, kidney, pancreas, heart, skin, bone
marrow, and other organs with the result that during the
last four to five years very important new insights into the
pathogenesis of fibrosis and of related diagnostic and
therapeutic options have been made [11]. Evolving patho-
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genetic concepts supplement the so called "canonical
principle" of liver fibrogenesis, which has been worked
out in detail during the last twenty years and which is
based, in principle, on the activation of hepatic stellate
cells (HSC).
The "canonical principle" of liver fibrogenesis
Fibrosis is characterized by a severalfold increase of the
extracellular matrix that comprises collagens, structural
glycoproteins, sulphated proteoglycans and hyaluronan,
by a histological redistribution with preferred initial
matrix deposition in the subendothelial space of Disse
leading to the formation of an incomplete subendothelial
basement membrane creating additional diffusion barri-
ers between hepatocytes and the liver sinusoid ("capillar-
ization of sinusoids"), and by changes in the
microstructure of collagens (e.g., degree of hydroxylation
of prolin and lysin), glycoproteins (variations of the car-
bohydrate structure) and proteoglycans (changes of the
degree of sulfation of the glycosaminoglycan side chains)
(Fig. 1). It is known for a long time that the increase of
ECM in the parenchyma is not a passive process caused by
condensation of pre-existing septa of connective tissue
due to necrotic and apoptotic collapse of the parenchyma,
instead, it is an active biosynthetic process, which is attrib-
uted to stimulated matrix production in portal or peribil-
iary fibroblasts and, in particular, in contractile
myofibroblasts (MFB) localized initially in the suben-
dothelial space of Disse. The development of MFB is the
result of a multi-step sequence, which originates from
liver cell necrosis induced by various noxious agents
(toxic, immunologic) [12,13] (Fig. 2). As a consequence,
HSC, formerly called vitamin A-storing cells, fat-storing
cells, arachnocytes, and Ito-cells [14,15], and localized in
the immediate vicinity of hepatocytes are activated (Fig.
3). HSC are liver pericytes, which embrace with thorn-like
microprojections the endothelial cell layer of the sinu-
soids providing physical contact not only to sinusoidal
endothelial cells, but also with the cell body to the hepa-
tocytes [16]. HSC constitute about 1/3 of the non-paren-
chymal cell population (Kupffer cells, endothelial cells,
HSC) and about 15% of total liver resident cells including
hepatocytes. The "hepatic stellate cell index", i. e., the
number of HSCs per 1000 hepatocytes was estimated to
be 109 in the healthy rat liver [17]. The spindle-like cell
body of HSC contains multiple triglyceride-rich vacuoles,
in which vitamin A metabolites (retinoids) are dissolved
and stored [18]. About 85% of the vitamin A of the liver
is found in HSC. Additional functions of these cells were
recently discovered: they seem to play a role as antigen
presenting cells (APC) [19-21], as CD133+ progenitor-
cells with the ability to differentiate to progenitor
endothelial cells and hepatocytes suggesting important
roles in liver regeneration and repair [22], they are
involved in endocytosis of apoptotic parenchymal cells
[23,24], in secretion of apolipoproteins, matrix metallo-
proteinases (MMPs), respective MMP-inhibitors (TIMPs)
[25,26] and growth factors [3], in the support of liver
regeneration through promotion of hepatocyte prolifera-
tion involving the neurotrophin receptor p75 [27], in reg-
ulation of angiogenesis and vascular remodelling through
secretion of angiogenic factors [28], and in hemodynamic
functions since activated HSC contract under stimulation
by thromboxan, prostaglandin F2, angiotensin II, vaso-
pressin, and endothelin-1 leading to sinusoidal constric-
tion [29-32]. Some of these functions, however, are not
expressed in the quiescent status of HSC, but are symp-
toms of their activation triggered by inflammatory media-
tors in consequence of liver cell damage. The activation of
HSC leads to the expression of α-smooth-muscle actin
and a loss of fat vacuoles combined with a decrease of
retinoids, but increases their contractility and strongly
their capacity to express and secrete a broad spectrum of
matrix components [3]. The activation process includes
proliferation and phenotypic transdifferentiation of HSC
to MFB, but both processes are not causally related. In the
"canonical principle" of fibrogenesis HSC-derived MFB
have the core competency not only for matrix synthesis,
but also for the expression and secretion of numerous
pro- and anti-inflammatory cytokines and growth factors
(Fig. 4). They have a highly synthetic phenotype character-
ized by a hypertrophic rough endoplasmic reticulum con-
taining ribosomes necessary for the synthesis of export
proteins. The mechanism of fibrogenic activation and
transdifferentiation of HSC to MFB can be summarized in
a three-step cascade model [33], which is initialized by the
pre-inflammatory phase due to direct paracrine activation
of HSC by necrotic (apoptotic?) hepatocytes with release
of activating cytokines supplemented by a loss of mito-
inhibitory cell surface heparan sulfate [34-38]. The growth
promoting activity of hepatocytes, partially due to IGF-1
and respective IGF-binding proteins [13], is released from
damaged cells and parallels the elevation of lactate dehy-
drogenase and aspartate aminotransferase as known leak-
age enzymes of hepatocytes [39]. In the following
inflammatory phase, the pre-activated HSC are further
stimulated in a paracrine mode by invaded leucocytes and
thrombocytes [40], but also by activated Kupffer cells
[36,41-44], sinusoidal endothelial cells and hepatocytes
[13,34,37] to transdifferentiate to MFB. The consecutive
postinflammatory phase is characterized by the secretion
of stimulating cytokines from MFB and interacting matrix
components. Some of these cytokines can stimulate in an
autocrine way MFB and in a paracrine mode resting HSC.
Thus, the postinflammatory phase contributes signifi-
cantly to the perpetuation of the fibrogenic process, even
after elimination or reduction of the pre-inflammatory
and inflammatory phases. Activation and transdifferenti-
ation of HSC is the result of extensive interactions with
liver-resident and non-resident cells (Fig. 5). Most rele-Comparative Hepatology 2007, 6:7 http://www.comparative-hepatology.com/content/6/1/7
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vant cellular mediators are reactive oxygen species
(hydroxyl radicals, oxygen radicals, superoxide anions,
hydrogen peroxide) produced by activated Kupffer cells
[41,45], the stimulated NAD(P)H oxidase activity of HSC
[46] phagocytosing apoptotic bodies [24], the cyto-
chrome P4502E1 (CYP2E1) pathway of ethanol-metabo-
lizing hepatocytes [47], and leucocytes [48]. In addition,
acetaldehyde of ethanol-exposed hepatocytes [49-52] and
tissue hypoxia [53] promote the activation of HSC.
Among the peptide mediators transforming growth factor
(TGF)-β turned out to be the fibrogenic master cytokine
[54-56]. Additional cytokines and growth factors involved
in fibrogenesis are platelet-derived growth factor B and D
(PDGF-B and PDGF-D), endothelin-1, several fibroblast
growth factors (FGFs), insulin-like growth factor I, tumor
necrosis factor (TNF)-α, adipocytokines (leptin, adi-
ponectin), and others, which are partly bound as
"crinopectins" [57] to the extracellular matrix [58]. The
matrix serves as a sponge for several of these growth fac-
tors fixed in a covalent or non-covalent manner to
fibronectin, proteoglycans and collagens. TGF-β, which is
secreted in a high molecular (large) latent form (Fig. 6) by
HSC/MFB, sinusoidal endothelial cells, and Kupffer cells
and released by destructed thrombocytes and hepatocytes
[59,60] initiates not only the activation of HSC to MFB,
but also enhances matrix gene expression, decreases their
degradation by down-modulation of matrix metallopro-
teinases and up-regulation of specific inhibitors (tissue
inhibitors of metalloproteinases, TIMPs), induces apopto-
sis of hepatocytes [61,62], and inhibits (together with
Matrix elements and fibrotic changes Figure 1
Matrix elements and fibrotic changes. Major components of the extracellular matrix (connective tissue) of the liver and 
the four most important changes in the fibrotic matrix.Comparative Hepatology 2007, 6:7 http://www.comparative-hepatology.com/content/6/1/7
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activin A) liver cell proliferation [63,64]. Extracellular
activation of latent TGF-β by proteases, oxygen radicals,
thrombospondin type I, and αvβ1,  α1β6 integrins is an
important step in the regulation of TGF-β bioavailability
[65]. Antagonism of TGF-β [66] or inhibition of its intra-
cellular Smad-signaling cascade by specific inhibitors [67]
leads to a significant retardation of HSC activation and
thus to a sustained antifibrotic effect. Interestingly, TGF-β
response and signalling are modulated during transdiffer-
entiation of HSC to MFB leading to their partial TGF-β
insensitivity [68]. This observation suggests a role of TGF-
β in the initiation of HSC activation in vivo but not a TGF-
β requirement for the entire transdifferentiation process
[69]. The activation of HSC to MFB in the chronically
inflamed liver is partially mimicked by primary cultures of
HSC, if these cells are plated on plastic surfaces instead of
extracellular matrices with no possibility of integrin
anchorage [70]. The model was previously suggested as a
valuable tool for studying the role of HSC in chronic liver
disease [71]. Accordingly, this cell culture system is quite
extensively used for testing of potentially antifibrotic
drugs, e.g., PPAR-γ agonists [72], trichostatin A, pirfeni-
done, halofuginone, scavengers of reactive oxygen species
(α-tocopherol, resveratrol, quercetin, curcumine), pro-
tease inhibitors, and others. However, a comparison of
the gene expression profiles of HSC activated in vivo by
bile-duct ligation or CCl4-injury with that of culture acti-
vated HSC could establish major differences [73]. Thus,
culture activation does not properly reflect genetic repro-
gramming of disease-driven HSC activation. Factors in the
microenvironment such as Kupffer cells and lipopolysac-
charides were identified to be relevant for the observed
Formal pathogenesis of liver fibrosis (fibrogenesis) Figure 2
Formal pathogenesis of liver fibrosis (fibrogenesis). The "canonical principle" of fibrogenesis starts with necrosis or 
apoptosis of hepatocytes and inflammation-connected activation of hepatic stellate cells (HSC triggering), their transdifferentia-
tion to myofibroblasts with enhanced expression and secretion of extracellular matrix and matrix deposition (fibrosis). The lat-
ter is a precondition for cirrhosis. New pathogenetic mechanisms concern the influx of bone marrow-derived cells (fibrocytes) 
and of circulating monocytes and their TGF-β driven differentiation to fibroblasts in the damaged liver tissue. A further new 
mechanism is epithelial-mesenchymal transition (EMT) of bile duct epithelial cells and potentially of hepatocytes. All three com-
plementary mechanisms enlarge the pool of matrix-synthesizing (myo-)fibroblasts in the damaged liver. The most important 
fibrogenic mediators are transforming growth factor (TGF)-β, platelet-derived growth factor (PDGF), insulin-like growth factor 
1 (IGF-1), endothelin-1 (ET-1), and reactive oxygen species (ROS including hydroxyl radicals, superoxid anions). Abbreviations: 
ASH – alcoholic steatohepatitis; NAFLD – non-alcoholic fatty liver disease. Inset shows an electron micrograph of HSC with 
numerous lipid droplets indenting the nucleus.Comparative Hepatology 2007, 6:7 http://www.comparative-hepatology.com/content/6/1/7
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differences [73]. Due to morphological and functional
intralobular (zonal) heterogeneity of HSC [74-76], the
processes of activation and transdifferentiation in situ are
slightly different, which is also dependent on the different
zonal vulnerability of hepatocytes. Accordingly, perivene-
ous hepatocytes around the central vein (acinus zone 3)
are the most sensitive and fibrogenesis, e. g., in alcoholic
liver injury, starts here first [77]. The heterogeneity of HSC
or MFB is not confined to their topographic localization,
but can also result from their origin, in particular since
morphological and functional criteria and the response to
growth factors point to different sources of origin of MFB
[78]. As an example, HSC express the cytoskeleton pro-
teins glial fibrillary acidic protein and desmin, which are
absent in MFB and the matrix protein reelin. MFB, how-
ever, almost exclusively synthesize the matrix protein
fibulin [79,80]. Using a dual reporter gene transgenic
mouse model of secondary biliary fibrosis (bile duct liga-
tion) it could be shown that peribiliary, parenchymal and
vascular fibrogenic cells expressed both transgenes (α-
smooth muscle actin and collagen α1 (I), respectively) dif-
ferentially indicating functional heterogeneity [81]. Taken
together, there is considerable uncertainty on the relation
between HSC and MFB suggesting several distinct myofi-
broblast-like cell types. Their composition and functional
role might be dependent on the nature of the underlying
disorder [82].
Contribution of bone marrow-derived cells to hepatic 
stellate cells, myofibroblasts, and fibroblasts in fibrotic 
liver tissue
Several studies have pointed to the bone marrow as a
source of immature, multipotent cells in various organs.
Bone marrow cells have the capacity to differentiate to
hepatocytes, cholangiocytes, sinusoidal endothelial cells,
and Kupffer cells, if the adequate micro-environment of
the liver is present [83,84]. This phenomenon is of great
importance for regenerative medicine (e.g., bone marrow
stem cell therapy). It was recently extended for HSC and
(myo-)fibroblasts under experimental and clinical condi-
Compilation of the most important components of extracel- lular matrix and of mediators synthesized by activated  hepatic stellate cells (HSC) Figure 4
Compilation of the most important components of 
extracellular matrix and of mediators synthesized by 
activated hepatic stellate cells (HSC). Abbreviations: 
CF – colony-stimulating factor; ET – endothelin; HGF – hepa-
tocyte growth factor; IGF – insulin-like growth factor; KGF – 
keratinocyte growth factor; LTBP – latent TGF-β binding 
protein; MCP – monocyte chemotactic peptide; MIP – mac-
rophage inflammatory protein; PAF – platelet activating fac-
tor; PDGF – platelet-derived growth factor; PGF – 
prostaglandin F; SF – scatter factor; TGF – transforming 
growth factor.
Schematic presentation of hepatic stellate cells (HSC) located  in the vicinity of adjacent hepatocytes (PC) beneath the sinu- soidal endothelial cells (EC) Figure 3
Schematic presentation of hepatic stellate cells 
(HSC) located in the vicinity of adjacent hepatocytes 
(PC) beneath the sinusoidal endothelial cells (EC). S – 
liver sinusoids; KC – Kupffer cells. Down left shows cultured 
HSC at light-microscopy, whereas at down right electron 
microscopy (EM) illustrates numerous fat vacuoles (L) in a 
HSC, in which retinoids are stored.Comparative Hepatology 2007, 6:7 http://www.comparative-hepatology.com/content/6/1/7
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tions. By transplantation of genetically tagged bone mar-
row or of male bone marrow (Y-chromosome) to female
mice, it was demonstrated that up to 30% of HSC in the
liver originate from the bone marrow and acquire the MFB
phenotype under injurious conditions [85]. Another
study indicates that up to 68% of HSC and 70% of MFB in
CCl4-cirrhotic mice liver derive from the bone marrow
[86]. Even in human liver fibrosis a significant contribu-
tion of bone marrow cells to the population of MFB was
proven, but it is presently unclear which type of specific
bone marrow cells or mesenchymal stem cells is relevant
for the generation of hepatic (myo-) fibroblasts [87].
Another experimental study shows that myelogenic fibro-
cytes are present in the liver, which can be differentiated
by TGF-β to collagen-producing MFB [88]. They are a sub-
population of circulating leucocytes, which display a
unique surface phenotype with CD45+ (haematopoietic
origin), CD34+ (progenitor cell), and type I collagen+
(capability of matrix synthesis) [89], and exhibit potent
immuno-stimulatory activities [90]. Fibrocytes represent a
systemic source of contractile MFB in various fibrotic
lesions, such as lung, keloids, scleroderma, and fibrotic
changes of the kidney [91]. The mobilization of bone
marrow cells and their recruitment into the damaged tis-
sue is a general mechanism of tissue fibrosis and wound
healing [92], which is most likely regulated by colony-
stimulating factors (CSF), such as granulocyte-CSF (G-
CSF) [93]. This mediator together with chemokines regu-
late the migration of bone marrow cells to sites of tissue
injury, but also the efflux from the bone marrow into the
circulation [90]. Activated HSC probably play an impor-
tant role since these cells secrete a broad spectrum of
inflammatory mediators (chemokines, M-CSF, SCF, PAF)
and leukocyte adhesion molecules (ICAM-1, VCAM-1,
NCAM) required for recruitment, activation, and matura-
tion of blood-born cells at the site of injury [94]. The
homing of myelogenic cells in the damaged liver was
claimed to also have a positive effect on the resolution of
liver fibrosis, since these cells express matrix metallopro-
teinases, which augment the degradation of fibrotic extra-
cellular matrix [93].
Contribution of peripheral blood cells to (myo-)fibroblasts 
of the liver
Recent studies indicate a highly developed multi-differen-
tiation potential of a subgroup of circulating blood
monocytes, which can be recruited quickly for tissue
repair processes [95]. In addition, the content of circulat-
ing myelogenic stem cells in the blood is suggested to be
important for regenerative mechanisms in consequence of
ischemic and degenerative diseases (i.e., myocardial inf-
arction). Investigations over the last years have proven
that peripheral blood monocytes can be differentiated in
vitro to hepatocyte-like cells if they are exposed with mac-
rophage-colony stimulating factor (M-CSF) and specific
interleukins (monocyte-derived neo-hepatocytes)
[96,97]. Although for liver fibrogenesis not yet proven,
subgroups of monocytes can differentiate into fibroblast-
like cells (fibrocytes) after entering the damaged tissue.
There they participate in fibrotic processes, e.g., of the lung
and kidney. The differentiation is positively influenced by
G-CSF, M-CSF, monocyte chemotactic peptide 1 (MCP-1),
and other chemokines and haematopoietic growth and
differentiation factors, which are expressed and secreted
by activated HSC [28,98-100] and other liver cell types
[101]. It is of interest that very recently an inhibitory effect
of the acute-phase protein serum amyloid P (SAP) on the
process of differentiation of monocytes to fibrocytes
could be established [102] and, consequently, a preven-
tive effect of SAP-injections on the development of bleo-
mycin-induced lung fibrosis was found [103]. C-reactive
protein (CRP) failed to show an inhibitory effect on the
differentiation of monocytes to fibrocytes. Since SAP is
synthesized in hepatocytes, severe liver injury might facil-
itate the monocyte-fibrocyte differentiation process due to
reduction of the inhibitory SAP. Although this mecha-
nism is presently somewhat speculative for the liver, circu-
lating monocytes might nonetheless be a pool for
immediate repair processes of liver damage. Beside special
monocytes as source of fibroblasts in the fibrotic liver, cir-
culating stem cells have to be considered, which are
CD34+ and CXCR4+ (a chemokine receptor) [95]. G-CSF
and the stromal derived factor (SDF)-1 are probably the
most important regulators of stem cell mobilisation from
bone-marrow and their integration into the damaged tis-
sue followed by differentiation to fibroblasts and other
cells.
Cellular interactions Figure 5
Cellular interactions. Synopsis of cellular interactions of 
resident liver cells (red) and immigrated inflammatory cells 
(green) with hepatic stellate cells in the process of activation 
and transdifferentiation to myofibroblasts. The most impor-
tant paracrine mediators are given.Comparative Hepatology 2007, 6:7 http://www.comparative-hepatology.com/content/6/1/7
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Epithelial-mesenchymal transition (EMT)
Beside activation and transdifferentiation of HSC, a cell
type, which is developmentally most likely derived from
the septum transversum mesenchyme, from endoderm or
from the mesothelial liver capsule [104], an increasing
number of experimental studies points to an additional
mechanism for the enlargement of the resident (local)
pool of fibroblasts during the fibrotic reaction of the dam-
aged organs, e.g., in kidney and lung [105]. This process,
termed epithelial-mesenchymal transition (EMT), is well
known in the context of embryonic development, but is
now discussed as an important mechanism in the genera-
tion of fibroblasts during fibrogenesis in adult tissues
[106] (Fig. 7). It was proven that in fibrotic kidney disease
tubulus epithelial cells can transdifferentiate to fibroblasts
expressing the fibroblast-specific protein 1 (FSP-1), also
known as S100A4 calcium-binding protein, and are able
to express collagens [106]. Similarly, alveolar epithelial
cells of the lung are subject to EMT and also cardial
endothelial cells can switch to fibroblasts under condi-
tions of damage (mesenchymal-mesenchymal transition).
It is estimated that in the kidney about 66% of fibroblasts
are the result of EMT, in the heart the number climbs to
about 20% (R. Kalluri, personal communication). In vitro
and in vivo observations made in blood vessels following
sustained inflammation support a hypothesis that
endothelial cell transformation to myofibroblast-like cells
may explain the increase of matrix proteins and of MFB
pathognomonic of fibrotic diseases [107]. Very recent
studies have also discussed EMT in liver fibrogenesis, after
a transition of albumin-positive hepatocytes to FSP-1 pos-
itive and albumin-negative fibroblasts was shown. Pre-
Extracellular matrix and TGF-β Figure 6
Extracellular matrix and TGF-β. Schematic presentation of intracellular TGF-β synthesis, secretion and extracellular 
immobilization via transglutaminase-dependent fixation of the large latent TGF-β binding protein (LTBP) to extracellular 
matrix, release by proteases and activation of the latent TGF-β complex by reactive oxygen species (ROS), specific integrins, 
thrombospondin-1 (TSP-1) or proteases with release of the active TGF-β homodimer, which binds to TGF-β receptors (TβR) 
III, II, and I to initiate the intracellular signalling cascade of Smad phosphorylation. Regulation of TGF-β occurs at the transcrip-
tional level and, most importantly, by extracellular activation. LAP – latency associated peptide.Comparative Hepatology 2007, 6:7 http://www.comparative-hepatology.com/content/6/1/7
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liminary studies claim that about 40% of hepatic
fibroblasts derive from hepatocytes, but these data need
further confirmation (R. Kalluri, personal communica-
tion). A very recent report provides evidence for EMT of
mature mouse hepatocytes in vitro and of the mouse hepa-
tocyte cell line AML12 [108]. The EMT-state was indicated
by strong up-regulation of α1(I) collagen mRNA expres-
sion and type I collagen deposition. Thus, hepatocytes are
capable of EMT changes and type I collagen synthesis. A
further source of EMT are cholangiocytes (bile duct epi-
thelial cells). In primary biliary cirrhosis (PBC) it was
proven that bile duct epithelial cells express FSP-1
(S100A4) and vimentin as early markers of fibroblasts
[109]. The bidirectional consequence of EMT of cholangi-
ocytes are ductopenia (reduction of bile ducts) and
enlargement of the pool of portal fibroblasts, which sig-
nificantly contributes to portal fibrosis. In vitro studies
with cultured human cholangiocytes have confirmed the
clinical observations described. Thus, EMT proves to be a
general pathogenetic principle of chronic cholestatic liver
diseases [110]. In addition, activation and proliferation of
portal/periportal mesenchymal cells to peribiliary MFB,
which are stimulated in a paracrine manner by bile duct
epithelial cells via TGF-β, PDGF-BB and endothelin-1
[111] turned out to be an important pathogenetic mecha-
nism of portal fibrosis and septa formation in cholestatic
liver diseases. Indeed, only a minority of ECM-producing
MFB in obstructive cholestatic injuries are derived from
HSC [112,113]. This also underlines the heterogeneous
origin of MFB in fibrogenesis and emphasizes the impor-
tance of the underlying fibrogenic liver disease [82].
The molecular inducers of EMT are TGF-β [106], epider-
mal growth factor (EGF), insulin-like growth factor (IGF)-
II, and fibroblast growth factor (FGF)-2, which promote
the genetic and phenotypic programming of epithelial
cells to mesenchymal cells (fibroblasts). The prototype of
the most powerful inducer of EMT is TGF-β. The inducing
function of TGF-β for the above described mesenchymal
transition of mouse hepatocytes was shown by activation
of Smad2/3 phosphorylation, inhibition by Smad4
silencing using siRNA and induction of the snail transcrip-
tion factor [108]. Interestingly, TGF-β induces EMT only
of those hepatocytes resisting to the pro-apoptotic effects
of this cytokine [114,115]. The subpopulation of surviv-
ing hepatocytes exhibits an overexpression of Snail by
TGF-β conferring resistance to programmed cell death
[116]. Several additional pathways are involved in the
generation of apoptosis resistance, e.g., proteinkinase A
[114] and epidermal growth factor (EGF)/TGF-α [115].
Thus, EMT of hepatocytes is dependent on the balance
between apoptotic and survival mechanisms. The process
of EMT also requires the action of metalloproteinases and
a TGF-β dependent down-regulation of E-cadherin both
contributing to the release of epithelial cells from cell-cell
and cell-basement membrane binding (Fig. 7). The most
important molecular counterpart is the bone morphoge-
netic protein (BMP)-7, also belonging to the TGF-β super-
family. BMP-7 not only inhibits EMT, but can even induce
a mesenchymal-epithelial transition (reverse EMT = MET)
[117]. It has anti-apoptotic properties, anti-inflammatory
and proliferation-stimulating effects [118]. BMP-7 inhib-
its TGF-β signalling via Smads [119], which transduce the
effect of the latter cytokine from its receptor, a serine/thre-
onine kinase, to the Smad-binding element (SBE) of
respective target genes in the nucleus [120]. In addition,
several trapping proteins such as the small proteoglycans
decorin and biglycan, latency associated peptide (LAP),
BAMBI (BMP and activin membrane-bound inhibitor),
KCP (kielin-chordin-like protein), gremlin, and α2-mac-
roglobulin change the balance between TGF-β and BMP-7
in favour of an anti-EMT effect due to binding a neutrali-
zation of TGF-β [121]. Similarly, the important down-
stream-modulator protein connective tissue growth factor
(CTGF/CCN2) [122], which is expressed in hepatocytes,
HSC, portal fibroblasts, and cholangiocytes [123,124]
changes the functional TGF-β/BMP-7 ratio [125]. CTGF is
over-expressed in experimental and human liver cirrhosis
[126-128], which is mediated mainly by TGF-β, but also
by endothelin-1, TNF-α, vascular endothelial growth fac-
tor (VEGF), nitrogen oxide (NO), prostaglandin E2,
thrombin, high glucose, and hypoxia [129]. CTGF inhib-
its BMP, but activates TGF-β signalling by modulation of
the receptor-binding of these ligands [123]. This is sup-
ported by very recent data, which show prominent antifi-
brotic effects of reduction of CTGF by siRNA [130,131].
Thus, depletion of CTGF greatly attenuates the develop-
Up-to-date mechanisms of fibrogenesis Figure 7
Up-to-date mechanisms of fibrogenesis. HSC activa-
tion, EMT, influx of fibrocytes, and differentiation of periph-
eral monocytes to fibroblasts at sites of injury. (Explanation is 
in the text).
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ment of experimental liver fibrosis. Taken together, both
EMT, but also MET, in special conditions even MMT (mes-
enchymal-mesenchymal transition, e.g., vascular
endothelial cells to fibroblasts), and the fine tuning of the
bioactive TGF-β/BMP-7 ratio and of their adaptor- and
trapping proteins offer multiple regulatory possibilities of
influencing fibrogenesis. These mechanisms are known in
some detail for the kidney [132], but need more experi-
mental proof for the liver, in particular with regard to its
quantitative contribution to fibrogenesis.
Options for diagnostic and therapy
Newly recognized pathogenetic mechanisms of fibrosis
described above provide several innovative options for
therapy of liver fibrogenesis and non-invasive diagnostic
strategies (Table 1). The determination of the TGF-β/BMP-
7 ratio in serum or plasma is potentially promising, since
this ratio might reflect the process of EMT and, thus, at
least partially the rate of progression of fibrosis. A decrease
of this ratio might indicate those patients with slow pro-
gression (slow fibroser), an increase a fast progression
(rapid fibroser). However, some precautions have to be
considered. The cytokine ratio in the circulation might be
not an accurate reflection of their activity at the immediate
environment of epithelial cells and fibroblasts, respec-
tively, and major fractions of these cytokines might be in
a biologically latent form. Thus, the protein ratio does not
necessarily mimic the diagnostically important activity
ratio of these mediators.
The determination of CTGF in serum or plasma is sug-
gested as a further innovative parameter of fibrogenesis,
since this modulator protein is strongly up-regulated in
the fibrotic liver, synthesized and secreted by parenchy-
mal and non-parenchymal cells [124] and since the action
of the profibrogenic TGF-β is stimulated but that of the
antifibrogenic BMP-7 is inhibited [123]. Preliminary stud-
ies point to significantly enhanced concentrations of
CTGF in blood of patients with active liver fibrogenesis
[133] in contrast to advanced cirrhosis with low activity of
active fibrogenesis, which is reflected by a relative
decrease of serum CTGF.
The flowcytometric detection of circulating fibrocytes in
blood or in buffy coat leucocytes by using CD34+, CD45+,
and collagen I positivities as identifying markers might be
a way for evaluation of their diagnostic potential. Alterna-
tively, these antigens might be detected by amplifying
their mRNA using a quantitative PCR approach. In addi-
tion, a re-evaluation of the high concentrations of G-CSF,
GM-CSF, and M-CSF in serum of cirrhotic patients pub-
lished previously [134] as mobilizers of bone marrow
cells and fibrocytes and of their integration into the dam-
aged liver tissue [135] might be a promising task. It
should be analyzed whether a systemic elevation of the
haematopoietic growth factors correlates with the activity
of liver fibrogenesis.
Table 1: Therapeutic and diagnostic options based on newly identified pathogenetic mechanisms of liver fibrosis
Parameter Pathobiochemical basis Potential serum markers of 
fibrosis
Therapeutic approach
TGF-β Fibrogenic master cytokine, up-
regulation in fibrotic liver; inducer of 
epithelial-mesenchymal transition 
(EMT)
Elevation by up-regulation in the fibrotic 
liver, release from necrotic hepatocytes 
and reduced hepatic clearance
Inhibition of TGF-β, blockade of 
intracellular signalling
BMP-7 TGF-β antagonist: anti-apoptotic; anti-
inflammatory; anti-EMT
Elevation in serum, indicator of slow 
fibrosis?
BMP-7 or BMP-7 peptide fragments 
antagonize TGF-β, antifibrotic effect, 
stimulation of liver regeneration
TGF-β/BMP-7 Ratio Determines epithelial-mesenchymal 
transition (EMT) and profibrogenic 
action of TGF-β
Potentially of prognostic significance for 
estimation of the progression rate of 
fibrosis (rapid versus slow fibrosis)
Modulation of the ratio by addition of 
recombinant BMP-7 has an antifibrotic 
effect
CTGF Down-stream modulator protein of 
TGF-β, influences functional TGF-β/
BMP-7 ratio by elevation of TGF-β and 
decrease of BMP-7 action
Elevation under conditions of active 
fibrogenesis, decrease with advancing 
cirrhosis and in the terminal stage 
without fibrogenic activity
Inhibition of CTGF expression by 
siRNAs or blocking with humanized 
monoclonal anti-CTGF antibodies (FG-
3019, FibroGen); has a strong 
antifibrotic effect
Fibrocytes Bone marrow-derived progenitor cells 
of fibroblasts increase the pool of 
fibroblasts in the fibrotic liver
Flow-cytometric detection of CD34+, 
CD45+, and collagen-1+ cells in 
peripheral blood or buffy coat 
leucocytes; potential indicator of 
increased influx into the damaged liver 
tissue
Hormonal modulation of release of 
fibrocytes from bone marrow and 
integration into the liver?
G-CSF Recruitment of bone marrow-derived 
cells in the circulation and stimulation 
of their homing in the fibrotic liver 
tissue
Elevated concentrations, relation to 
fibrogenesis not yet established
G-CSF triggered haematopoietic stem 
cells or G-CSF itself accelerates healing 
of experimental liver damage and 
improves the survival rateComparative Hepatology 2007, 6:7 http://www.comparative-hepatology.com/content/6/1/7
Page 10 of 13
(page number not for citation purposes)
Numerous publications discuss anti-fibrotic therapeutic
strategies by inhibition of TGF-β [9,67,136-138], but the
systemic application of inhibitors and consequently an
overall and ubiquitous reduction of TGF-β activity will
most likely have severe side effects, i.e., on tumor develop-
ment and progression, auto-immunopathy and degenera-
tive diseases [139]. Therefore, the therapeutic application
of recombinant human BMP-7 or functionally active
BMP-7 fragments might be advantageous since BMP-7
inhibits experimental fibrosis in rats [140], stimulates
liver regeneration [118], and inhibits TGF-β-driven paren-
chymal cell apoptosis due to its antagonism of TGF-β.
Experimental trials with thioacetamide-induced rat liver
fibrosis point to successful antifibrotic results [140]. Sim-
ilarly, extensive studies with experimental kidney diseases
prove that BMP-7 can induce MET and, thus, has regener-
ative and antifibrotic effects [141]. Presently, it is not
known whether the positive CTGF-inhibitory experiments
for suppression of experimental fibrosis [130,131] can be
translated into clinical practice, but studies – in which
CTGF activity is reduced by systemic application of a
humanized, monoclonal, blocking antibody (F-3019),
which neutralizes and accelerates the clearance of this pro-
tein [142] – are in progress and point to successful prelim-
inary results. Pathophysiologically, the inhibitors of CTGF
should have fibro-suppressive effects since the TGF-β/
BMP-7 ratio is switched in favour of BMP-7. This was
recently shown by inhibition of CTGF expression
[130,131]. In conclusion, further intensive studies are
required to translate the positive results of cell culture
studies and of animal experiments into clinical applica-
tion. The new pathogenetic insights justify strong opti-
mism since the spectrum of potential approaches to
interfere with the fibrogenic pathway are greatly broad-
ened.
Conclusion
The above described changing view on the pathogenetic
mechanisms of liver fibrosis clearly suggests that one has
to reconsider the exclusive role of HSC in the develop-
ment of fibrosis. Although some of the newly proposed
fibrogenic mechanisms have to be consolidated by addi-
tional experimental evidence in vitro and in situ, they
indicate the presence of distinct subpopulations of myofi-
broblasts/fibroblasts in fibrosing liver, of which HSC-
derived fibrogenic cells are only one of several sources.
Most important, the composition of (myo-)fibroblasts
may vary with the etiology of fibrosis, e.g., primary biliary
cirrhosis might activate a pathogenetic pathway different
from alcoholic fibrosis. These facts point to the important
notion that results obtained with various models of exper-
imental fibrogenesis cannot be generalized because differ-
ent classes of (myo-)fibroblasts are generated by diverse
pathways. Furthermore, HSC-activation in culture cannot
be regarded any longer as the almost dogmatic paradigm
of the liver fibrogenic mechanism as it was in the past.
Since now detailed information on the molecular cas-
cades of intracellular fibrogenic signaling is available, we
have learned that several of them are modulated cell-type
specifically. Therefore, it is conceivable that distinct sub-
populations of fibroblasts and their transient precursor
cell types respond differently to major fibrogenic
cytokines, e.g., TGF-β. If this is the case, the complexity of
the fibrogenic mechanisms will increase strongly in the
future and the experimental conditions have to be
described in detail. Taken together, studies on fibrogene-
sis in the liver (and other organs as well) are now pushed
forward a lot, hopefully resulting in new impulses for
therapy and diagnosis.
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